Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Utilizing Peptide Ligand GPCRs to Image and Treat Pancreatic Cancer.

Matters GL, Harms JF.

Biomedicines. 2018 Jun 2;6(2). pii: E65. doi: 10.3390/biomedicines6020065. Review.

2.

Correction to Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

Helal CJ, Arnold EP, Boyden TL, Chang C, Chappie TA, Fennell KF, Forman MD, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Kang Z, Kleiman RJ, Kormos BL, LaChapelle EA, Lee CW, Lu J, Maklad N, McDowell L, Mente S, O'Connor RE, Pandit J, Piotrowski M, Schmidt AW, Schmidt CJ, Ueno H, Verhoest PR, Yang EX.

J Med Chem. 2018 Apr 26;61(8):3753. doi: 10.1021/acs.jmedchem.8b00475. Epub 2018 Apr 6. No abstract available.

PMID:
29624389
3.

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.

Helal CJ, Arnold E, Boyden T, Chang C, Chappie TA, Fisher E, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Pandit J, Kang Z, Kleiman RJ, Kormos BL, Lee CW, Lu J, Maklad N, McDowell L, McGinnis D, O'Connor RE, O'Donnell CJ, Ogden A, Piotrowski M, Schmidt CJ, Seymour PA, Ueno H, Vansell N, Verhoest PR, Yang EX.

J Med Chem. 2018 Feb 8;61(3):1001-1018. doi: 10.1021/acs.jmedchem.7b01466. Epub 2018 Jan 16.

PMID:
29293004
4.

Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

Helal CJ, Arnold EP, Boyden TL, Chang C, Chappie TA, Fennell KF, Forman MD, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Kang Z, Kleiman RJ, Kormos BL, Lee CW, Lu J, Maklad N, McDowell L, Mente S, O'Connor RE, Pandit J, Piotrowski M, Schmidt AW, Schmidt CJ, Ueno H, Verhoest PR, Yang EX.

J Med Chem. 2017 Jul 13;60(13):5673-5698. doi: 10.1021/acs.jmedchem.7b00397. Epub 2017 Jun 16. Erratum in: J Med Chem. 2018 Apr 26;61(8):3753.

PMID:
28574706
5.

Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.

Beaumont V, Zhong S, Lin H, Xu W, Bradaia A, Steidl E, Gleyzes M, Wadel K, Buisson B, Padovan-Neto FE, Chakroborty S, Ward KM, Harms JF, Beltran J, Kwan M, Ghavami A, Häggkvist J, Tóth M, Halldin C, Varrone A, Schaab C, Dybowski JN, Elschenbroich S, Lehtimäki K, Heikkinen T, Park L, Rosinski J, Mrzljak L, Lavery D, West AR, Schmidt CJ, Zaleska MM, Munoz-Sanjuan I.

Neuron. 2016 Dec 21;92(6):1220-1237. doi: 10.1016/j.neuron.2016.10.064. Epub 2016 Dec 1.

6.

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A.

Alexander MS, Gasperini MJ, Tsai PT, Gibbs DE, Spinazzola JM, Marshall JL, Feyder MJ, Pletcher MT, Chekler EL, Morris CA, Sahin M, Harms JF, Schmidt CJ, Kleiman RJ, Kunkel LM.

Transl Psychiatry. 2016 Sep 27;6(9):e901. doi: 10.1038/tp.2016.174.

7.

Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.

Padovan-Neto FE, Sammut S, Chakroborty S, Dec AM, Threlfell S, Campbell PW, Mudrakola V, Harms JF, Schmidt CJ, West AR.

J Neurosci. 2015 Apr 8;35(14):5781-91. doi: 10.1523/JNEUROSCI.1238-14.2015.

8.

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.

Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, Harms JF, Helal CJ, Hoffmann WE, Kocan GP, Majchrzak MJ, McGinnis D, McLean S, Menniti FS, Nelson F, Roof R, Schmidt AW, Seymour PA, Stephenson DT, Tingley FD, Vanase-Frawley M, Verhoest PR, Schmidt CJ.

J Pharmacol Exp Ther. 2012 May;341(2):396-409. doi: 10.1124/jpet.111.191353. Epub 2012 Feb 10.

PMID:
22328573
9.

A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer.

Smith JP, Harms JF, Matters GL, McGovern CO, Ruggiero FM, Liao J, Fino KK, Ortega EE, Gilius EL, Phillips JA 3rd.

Cancer Biol Ther. 2012 Feb 1;13(3):164-74. doi: 10.4161/cbt.13.3.18698. Epub 2012 Feb 1.

10.

Role of endogenous cholecystokinin on growth of human pancreatic cancer.

Matters GL, McGovern C, Harms JF, Markovic K, Anson K, Jayakumar C, Martenis M, Awad C, Smith JP.

Int J Oncol. 2011 Mar;38(3):593-601. doi: 10.3892/ijo.2010.886. Epub 2010 Dec 24.

11.

Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.

Kleiman RJ, Kimmel LH, Bove SE, Lanz TA, Harms JF, Romegialli A, Miller KS, Willis A, des Etages S, Kuhn M, Schmidt CJ.

J Pharmacol Exp Ther. 2011 Jan;336(1):64-76. doi: 10.1124/jpet.110.173294. Epub 2010 Oct 5.

PMID:
20923867
12.

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F, O'Connor R, Pandit J, Proulx-Lafrance C, Schmidt AW, Schmidt CJ, Suiciak JA, Liras S.

J Med Chem. 2009 Aug 27;52(16):5188-96. doi: 10.1021/jm900521k.

PMID:
19630403
13.

Growth of human pancreatic cancer is inhibited by down-regulation of gastrin gene expression.

Matters GL, Harms JF, McGovern CO, Jayakumar C, Crepin K, Smith ZP, Nelson MC, Stock H, Fenn CW, Kaiser J, Kester M, Smith JP.

Pancreas. 2009 Jul;38(5):e151-61. doi: 10.1097/MPA.0b013e3181a66fdc.

14.

The opioid antagonist naltrexone improves murine inflammatory bowel disease.

Matters GL, Harms JF, McGovern C, Fitzpatrick L, Parikh A, Nilo N, Smith JP.

J Immunotoxicol. 2008 Apr;5(2):179-87. doi: 10.1080/15476910802131469.

PMID:
18569389
15.

Vagotomy enhances experimental metastases of 4THMpc breast cancer cells and alters substance P level.

Erin N, Akdas Barkan G, Harms JF, Clawson GA.

Regul Pept. 2008 Nov 29;151(1-3):35-42. doi: 10.1016/j.regpep.2008.03.012. Epub 2008 Apr 3.

PMID:
18499282
16.

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS.

J Pharmacol Exp Ther. 2008 May;325(2):681-90. doi: 10.1124/jpet.107.132910. Epub 2008 Feb 20.

PMID:
18287214
17.

Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background.

Siuciak JA, McCarthy SA, Chapin DS, Martin AN, Harms JF, Schmidt CJ.

Neuropharmacology. 2008 Feb;54(2):417-27. Epub 2007 Dec 3.

PMID:
18061215
18.

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):386-96. Epub 2006 Jun 15.

PMID:
16780899
19.

Kinetics of metastatic breast cancer cell trafficking in bone.

Phadke PA, Mercer RR, Harms JF, Jia Y, Frost AR, Jewell JL, Bussard KM, Nelson S, Moore C, Kappes JC, Gay CV, Mastro AM, Welch DR.

Clin Cancer Res. 2006 Mar 1;12(5):1431-40.

20.

Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis.

Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S, Goldsmith CM, Piper JT, Vostal JG, Harms JF, Welch DR, Kleinman HK.

Cancer Res. 2005 Aug 15;65(16):7370-7.

21.

Breast cancer metastasis to bone: evolving models and research challenges.

Welch DR, Harms JF, Mastro AM, Gay CV, Donahue HJ.

J Musculoskelet Neuronal Interact. 2003 Mar;3(1):30-8. No abstract available.

22.

A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.

Harms JF, Welch DR, Samant RS, Shevde LA, Miele ME, Babu GR, Goldberg SF, Gilman VR, Sosnowski DM, Campo DA, Gay CV, Budgeon LR, Mercer R, Jewell J, Mastro AM, Donahue HJ, Erin N, Debies MT, Meehan WJ, Jones AL, Mbalaviele G, Nickols A, Christensen ND, Melly R, Beck LN, Kent J, Rader RK, Kotyk JJ, Pagel MD, Westlin WF, Griggs DW.

Clin Exp Metastasis. 2004;21(2):119-28.

PMID:
15168729
23.

Pericyte-like location of GFP-tagged melanoma cells: ex vivo and in vivo studies of extravascular migratory metastasis.

Lugassy C, Kleinman HK, Engbring JA, Welch DR, Harms JF, Rufner R, Ghanem G, Patierno SR, Barnhill RL.

Am J Pathol. 2004 Apr;164(4):1191-8.

24.

MDA-MB-435 human breast carcinoma metastasis to bone.

Harms JF, Welch DR.

Clin Exp Metastasis. 2003;20(4):327-34.

PMID:
12856720
25.

Effects of alpha-difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice.

Manni A, Washington S, Craig L, Cloud M, Griffith JW, Verderame MF, Texter LJ, Mauger D, Demers LM, Harms JF, Welch DR.

Clin Exp Metastasis. 2003;20(4):321-5.

PMID:
12856719
26.

KISS1 metastasis suppression and emergent pathways.

Harms JF, Welch DR, Miele ME.

Clin Exp Metastasis. 2003;20(1):11-8. Review.

PMID:
12650602
27.

Maintaining GFP tissue fluorescence through bone decalcification and long-term storage.

Harms JF, Budgeon LR, Christensen ND, Welch DR.

Biotechniques. 2002 Dec;33(6):1197-200. No abstract available.

28.

Analysis of mechanisms underlying BRMS1 suppression of metastasis.

Samant RS, Seraj MJ, Saunders MM, Sakamaki TS, Shevde LA, Harms JF, Leonard TO, Goldberg SF, Budgeon L, Meehan WJ, Winter CR, Christensen ND, Verderame MF, Donahue HJ, Welch DR.

Clin Exp Metastasis. 2000;18(8):683-93.

PMID:
11827072
29.

Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate.

Goldberg SF, Harms JF, Quon K, Welch DR.

Clin Exp Metastasis. 1999;17(7):601-7.

PMID:
10845559
30.

Supplemental Content

Loading ...
Support Center